Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

Malhotra A, Grunstein R, Azarbarzin A, Sands S, Somers VK, Aronne LJ, Jastreboff AM, Lou J, Chakladar S, Dunn JP, Bunck MC, Bednarik J

Nature medicine15 Jan 2026Cited by 15 (Europe PMC)

PMID41540105PMCIDPMC12920140DOI10.1038/s41591-025-04071-1PepBankPUB-41540105

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obstructive sleep apnea and obesity, tirzepatide was associated with greater alleviation of cardiometabolic risk factors than placebo in both SURMOUNT-OSA studies.
In plain wordsIn adults with sleep apnea and obesity, tirzepatide improved heart and metabolic risk factors more than placebo in both trials.
Peptide
Tirzepatide
Outcome
DecreaseCardiometabolic risk factors
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
In both study 1 and study 2 of SURMOUNT-OSA, tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010501
02HumanRandomized controlled trialMechanism
In adults with obstructive sleep apnea and obesity, changes in OSA metrics independently mediated the tirzepatide effect on high-sensitivity C-reactive protein.
In plain wordsIn adults with sleep apnea and obesity, part of tirzepatide's effect on an inflammation marker (hs-CRP) was linked to changes in sleep apnea measures.
Peptide
Tirzepatide
Outcome
Not applicableMediation of hs-CRP change by OSA metrics
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010502
03HumanRandomized controlled trialMechanism
In adults with obstructive sleep apnea and obesity, changes in OSA metrics independently mediated the tirzepatide effect on insulin resistance (HOMA-IR).
In plain wordsIn adults with sleep apnea and obesity, part of tirzepatide's effect on insulin resistance was linked to changes in sleep apnea measures.
Peptide
Tirzepatide
Outcome
Not applicableMediation of HOMA-IR change by OSA metrics
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides.
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010503
04HumanRandomized controlled trialMechanism
In adults with obstructive sleep apnea and obesity, changes in OSA metrics independently mediated the tirzepatide effect on triglycerides.
In plain wordsIn adults with sleep apnea and obesity, part of tirzepatide's effect on triglycerides was linked to changes in sleep apnea measures.
Peptide
Tirzepatide
Outcome
Not applicableMediation of triglyceride change by OSA metrics
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides.
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010504
05HumanRandomized controlled trialMechanism
In adults with obstructive sleep apnea and obesity, weight change alone, and weight change with OSA metric changes, significantly mediated the tirzepatide effect on systolic blood pressure.
In plain wordsIn adults with sleep apnea and obesity, part of tirzepatide's effect on systolic blood pressure was linked to weight change and sleep apnea measures.
Peptide
Tirzepatide
Outcome
Not applicableMediation of systolic blood pressure change by weight and OSA metrics
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
The combination of changes in weight and OSA metrics, as well as weight alone, had a significant mediation effect on systolic blood pressure
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010505
06HumanRandomized controlled trialMechanism
In adults with obstructive sleep apnea and obesity, neither weight nor OSA metrics significantly mediated the tirzepatide effect on diastolic blood pressure.
In plain wordsIn adults with sleep apnea and obesity, weight and sleep apnea changes did not explain tirzepatide's effect on diastolic blood pressure.
Peptide
Tirzepatide
Outcome
No significant changeMediation of diastolic blood pressure change by weight and OSA metrics
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
but there was no significant mediation effect of weight or OSA metrics observed on diastolic blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide.
Report a problemFND-4154010506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05412004

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Eli Lilly and Companyn = 46921 Jun 2022 to 29 Mar 2024

Obstructive Sleep Apnea · Obesity

Trial page ClinicalTrials.govUpdated 30 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.